Precision oncology of spatial immune escape mechanisms in ovarian cancer
This project aims to exploit tumor genetic drivers of immune escape in high-grade serous ovarian cancer to develop effective immunotherapies through advanced profiling and functional testing of patient-derived organoids.
Projectdetails
Introduction
Tumor progression is dependent on the ability of malignant cells to escape the recognition and attack by the host immune system. The development of more efficient cancer immunotherapies has been hampered by the perplexity of immune escape mechanisms. I hypothesize that tumor genetic drivers dictate the immune escape mechanisms, and that these mechanisms can be exploited to develop more effective immunotherapeutic strategies for patients with high-grade serous ovarian cancer (HGSC), the most common and lethal ovarian cancer.
Methodology
My group has developed an optimized algorithm based on homologous recombination (HR) DNA repair deficiency to enable clinically meaningful stratification of the complex HGSC genotypes.
Immunogenicity Profiling
We will define the immunogenicity of the HGSC genotypes via profiling:
- Tumor somatic mutations and neoantigens
- Cell-type specific gene expressions
- T/B cell receptor diversities
This will be conducted using over 600 HGSC samples.
Spatial Analysis
Using a cutting-edge highly multiplexed technology and advanced image analysis, we will reveal the single-cell spatial landscapes of the tumor microenvironment in 200 immunogenetically-defined HGSCs.
We will apply pioneering spatial analyses on the single-cell data and use artificial intelligence to uncover clinically relevant spatial biology of HGSCs.
Transcriptomic Profiling
Via transcriptomic profiling of 384 spatial microregions, we will discover the detailed immune escape mechanisms of the HGSC genotypes.
Functional Testing
For functional testing, we have developed a groundbreaking method to establish immune-competent patient-derived organoids (iPDOs), which faithfully recapitulate the patients' tumors.
Using our high-throughput iPDO functional platform, we will:
- Test mechanism-specific immunotherapeutic approaches
- Capture the treatment responses at single-cell resolution
Conclusion
The discovery and functional targeting of the immune escape mechanisms gives us unprecedented potential to open new horizons in immunotherapeutic targeting of HGSC.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.368.459 |
Totale projectbegroting | € 2.368.459 |
Tijdlijn
Startdatum | 1-2-2023 |
Einddatum | 31-1-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HELSINGIN YLIOPISTOpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Unravelling Tumour Biology In Ovarian Cancer With Precision ImagingThis project aims to utilize a multiscale radiomics approach to non-invasively characterize tumor heterogeneity in high-grade serous ovarian cancer, linking imaging features to underlying tumor biology. | ERC Starting... | € 1.474.150 | 2023 | Details |
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancerThis project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations. | ERC Consolid... | € 1.999.754 | 2024 | Details |
Cancer cell plasticity on targeted therapyThis project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Unlocking a T cell-mediated Immune response in therapy-challenged TumorsUnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors. | ERC Consolid... | € 2.000.000 | 2024 | Details |
Spatial Quantification of Cellular Metabolism in the Tumor Immune MicroenvironmentThis project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment. | ERC Starting... | € 1.497.756 | 2023 | Details |
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
This project aims to utilize a multiscale radiomics approach to non-invasively characterize tumor heterogeneity in high-grade serous ovarian cancer, linking imaging features to underlying tumor biology.
What doesn’t kill you: primed and adaptive mechanisms of treatment resistance in ovarian cancer
This project aims to develop a novel methodology to identify and target pre-existing resistant cell states in ovarian cancer, enhancing therapy effectiveness through sequential drug combinations.
Cancer cell plasticity on targeted therapy
This project aims to develop innovative cancer therapies by analyzing tumor heterogeneity and targeting drug-tolerant persister cells to prevent resistance and improve patient outcomes.
Unlocking a T cell-mediated Immune response in therapy-challenged Tumors
UnlockIT aims to develop mechanism-based combination therapies for cancer by understanding tumor-immune interactions and enhancing T cell responses in therapy-challenged tumors.
Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment
This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancerErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients. | EIC Accelerator | € 2.499.999 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Macrophage-based immunotherapy of platinum-resistant ovarian cancerThe MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies. | EIC Transition | € 2.499.998 | 2022 | Details |
Development of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer
ErVaccine aims to develop TCR-OV1, a novel TCR-T cell therapy targeting cancer-specific antigens to improve early detection and treatment outcomes for ovarian cancer patients.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Macrophage-based immunotherapy of platinum-resistant ovarian cancer
The MACOV project aims to develop a groundbreaking macrophage-based therapy for platinum-resistant ovarian cancer, preparing it for Phase I clinical trials through comprehensive pre-clinical efficacy and safety studies.